Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Inhibrx Biosciences Inc (NASDAQ: INBX) closed the day trading at $78.51 up 1.89% from the previous closing price of $77.05. In other words, the price has increased by $1.89 from its previous closing price. On the day, 0.95 million shares were traded. INBX stock price reached its highest trading level at $83.782 during the session, while it also had its lowest trading level at $74.1077.
Ratios:
For a better understanding of INBX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.98 and its Current Ratio is at 4.98. In the meantime, Its Debt-to-Equity ratio is 1.56 whereas as Long-Term Debt/Eq ratio is at 1.53.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 07 ’25 when VIKING GLOBAL INVESTORS LP sold 350,000 shares for $32.25 per share. The transaction valued at 11,287,500 led to the insider holds 67,018 shares of the business.
Kayyem Jon Faiz bought 69,686 shares of INBX for $991,416 on Nov 19 ’24. The Director now owns 51,093 shares after completing the transaction at $14.23 per share. On Nov 20 ’24, another insider, Kayyem Jon Faiz, who serves as the Director of the company, bought 37,500 shares for $14.19 each. As a result, the insider paid 532,204 and bolstered with 69,843 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INBX now has a Market Capitalization of 1137250432 and an Enterprise Value of 1057472384. For the stock, the TTM Price-to-Sale (P/S) ratio is 812.32 while its Price-to-Book (P/B) ratio in mrq is 16.58. Its current Enterprise Value per Revenue stands at 755.337 whereas that against EBITDA is -10.996.
Stock Price History:
The Beta on a monthly basis for INBX is 1.61, which has changed by 3.9689875 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, INBX has reached a high of $77.57, while it has fallen to a 52-week low of $10.81. The 50-Day Moving Average of the stock is 128.62%, while the 200-Day Moving Average is calculated to be 292.37%.
Shares Statistics:
Over the past 3-months, INBX traded about 275.18K shares per day on average, while over the past 10 days, INBX traded about 1191480 shares per day. A total of 14.48M shares are outstanding, with a floating share count of 9.86M. Insiders hold about 31.91% of the company’s shares, while institutions hold 56.89% stake in the company. Shares short for INBX as of 1760486400 were 532661 with a Short Ratio of 1.94, compared to 1757894400 on 721500. Therefore, it implies a Short% of Shares Outstanding of 532661 and a Short% of Float of 5.07.
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of Inhibrx Biosciences Inc (INBX) in the stock market.The consensus estimate for the next quarter is -$1.75, with high estimates of -$1.75 and low estimates of -$1.75.
Analysts are recommending an EPS of between -$8.12 and -$8.12 for the fiscal current year, implying an average EPS of -$8.12. EPS for the following year is -$9.32, with 1.0 analysts recommending between -$9.32 and -$9.32.
